182 related articles for article (PubMed ID: 20142835)
41. Reconstitution models to evaluate natural killer T cell function in tumor control.
Gebremeskel S; Slauenwhite D; Johnston B
Immunol Cell Biol; 2016 Jan; 94(1):90-100. PubMed ID: 26095148
[TBL] [Abstract][Full Text] [Related]
42. α-Galactosylceramide-activated murine NK1.1(+) invariant-NKT cells in the myometrium induce miscarriages in mice.
Ichikawa T; Negishi Y; Shimizu M; Takeshita T; Takahashi H
Eur J Immunol; 2016 Aug; 46(8):1867-77. PubMed ID: 27198610
[TBL] [Abstract][Full Text] [Related]
43. Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties.
Choi J; Rudak PT; Lesage S; Haeryfar SMM
J Immunol; 2019 Oct; 203(7):1808-1819. PubMed ID: 31462506
[TBL] [Abstract][Full Text] [Related]
44. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells.
Uemura Y; Liu TY; Narita Y; Suzuki M; Nakatsuka R; Araki T; Matsumoto M; Iwai LK; Hirosawa N; Matsuoka Y; Murakami M; Kimura T; Hase M; Kohno H; Sasaki Y; Ichihara Y; Ishihara O; Kikuchi H; Sakamoto Y; Jiao SC; Senju S; Sonoda Y
J Immunol; 2009 Jul; 183(1):201-8. PubMed ID: 19542431
[TBL] [Abstract][Full Text] [Related]
45. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.
Biburger M; Tiegs G
J Leukoc Biol; 2008 Jul; 84(1):264-79. PubMed ID: 18407967
[TBL] [Abstract][Full Text] [Related]
46. Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation.
Wang J; Cho S; Ueno A; Cheng L; Xu BY; Desrosiers MD; Shi Y; Yang Y
J Immunol; 2008 Aug; 181(4):2438-45. PubMed ID: 18684934
[TBL] [Abstract][Full Text] [Related]
47. KLRG+ invariant natural killer T cells are long-lived effectors.
Shimizu K; Sato Y; Shinga J; Watanabe T; Endo T; Asakura M; Yamasaki S; Kawahara K; Kinjo Y; Kitamura H; Watarai H; Ishii Y; Tsuji M; Taniguchi M; Ohara O; Fujii S
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12474-9. PubMed ID: 25118276
[TBL] [Abstract][Full Text] [Related]
48. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
[TBL] [Abstract][Full Text] [Related]
49. Differential dendritic cell-mediated activation and functions of invariant NKT-cell subsets in oral cancer.
Singh AK; Gaur P; Shukla NK; Das SN
Oral Dis; 2015 Jan; 21(1):e105-13. PubMed ID: 24654917
[TBL] [Abstract][Full Text] [Related]
50. Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.
Fox LM; Miksanek J; May NA; Scharf L; Lockridge JL; Veerapen N; Besra GS; Adams EJ; Hudson AW; Gumperz JE
Cancer Immun; 2013; 13():9. PubMed ID: 23885215
[TBL] [Abstract][Full Text] [Related]
51. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
52. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
Front Immunol; 2020; 11():990. PubMed ID: 32536918
[TBL] [Abstract][Full Text] [Related]
53. Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma.
Grasso C; Field CS; Tang CW; Ferguson PM; J Compton B; Anderson RJ; Painter GF; Weinkove R; F Hermans I; Berridge MV
Immunotherapy; 2020 Apr; 12(6):395-406. PubMed ID: 32316797
[No Abstract] [Full Text] [Related]
54. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection.
Reilly EC; Thompson EA; Aspeslagh S; Wands JR; Elewaut D; Brossay L
PLoS One; 2012; 7(5):e37991. PubMed ID: 22649570
[TBL] [Abstract][Full Text] [Related]
55. Combined proinflammatory cytokine and cognate activation of invariant natural killer T cells enhances anti-DNA antibody responses.
Sedimbi SK; Hägglöf T; Garimella MG; Wang S; Duhlin A; Coelho A; Ingelshed K; Mondoc E; Malin SG; Holmdahl R; Lane DP; Leadbetter EA; Karlsson MCI
Proc Natl Acad Sci U S A; 2020 Apr; 117(16):9054-9063. PubMed ID: 32295878
[TBL] [Abstract][Full Text] [Related]
56. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
[TBL] [Abstract][Full Text] [Related]
57. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma.
Liu H; Chen L; Liu J; Meng H; Zhang R; Ma L; Wu L; Yu S; Shi F; Li Y; Zhang L; Wang L; Feng S; Zhang Q; Peng Y; Wu Q; Liu C; Chang X; Yang L; Uemura Y; Yu X; Liu T
Cancer Lett; 2017 Dec; 411():182-190. PubMed ID: 28947140
[TBL] [Abstract][Full Text] [Related]
58. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
[TBL] [Abstract][Full Text] [Related]
59. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
60. Invariant NKT cells suppress CD8(+) T-cell-mediated allergic contact dermatitis independently of regulatory CD4(+) T cells.
Goubier A; Vocanson M; Macari C; Poyet G; Herbelin A; Nicolas JF; Dubois B; Kaiserlian D
J Invest Dermatol; 2013 Apr; 133(4):980-7. PubMed ID: 23190881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]